Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DuACT is a fixed-dose combination medication designed to alleviate symptoms associated with seasonal and perennial allergic rhinitis. It comprises two active pharmaceutical ingredients: Acrivastine, an H1-antihistamine, and Pseudoephedrine, a sympathomimetic decongestant. Acrivastine functions by blocking histamine H1 receptors, thereby reducing allergic reactions such as sneezing, itching, and runny nose. Pseudoephedrine exerts its effect by stimulating alpha and beta adrenergic receptors, leading to vasoconstriction in the nasal passages, which in turn reduces swelling and mucus production, providing relief from nasal congestion. This medication is typically administered orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DuACT.